{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:32:23Z","timestamp":1772811143451,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.contraception.2010.04.013","type":"journal-article","created":{"date-parts":[[2010,7,12]],"date-time":"2010-07-12T00:47:23Z","timestamp":1278895643000},"page":"358-365","source":"Crossref","is-referenced-by-count":4,"title":["Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24\/4-day regimen over six cycles"],"prefix":"10.1016","volume":"82","author":[{"given":"Thomas","family":"Rabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Hartschuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Wahlstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelia","family":"H\u00f6schen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2010.04.013_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/bmj.2.5703.231","article-title":"A statement by the Committee on Safety of Drugs","volume":"2","author":"Combined oral contraceptives","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.contraception.2010.04.013_bib2","first-page":"1058","article-title":"Recommendations on oral contraception","volume":"38","author":"Bettendorf","year":"1997","journal-title":"Der Frauenarzt"},{"key":"10.1016\/j.contraception.2010.04.013_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/bmj.2.5704.293","article-title":"R.C.O.G. statement on oral contraceptives","volume":"2","author":"Jeffcoate","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.contraception.2010.04.013_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.contraception.2008.10.017","article-title":"Profile of the progesterone derivative chlormadinone acetate \u2014 pharmacodynamic properties and therapeutic applications","volume":"79","author":"Druckmann","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.contraception.2009.02.016","article-title":"Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial","volume":"80","author":"Plewig","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00044011-200222040-00002","article-title":"Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg\/ethinylestradiol 0.03 mg (Belara). Results of a post-marketing surveillance study","volume":"22","author":"Schramm","year":"2002","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.contraception.2010.04.013_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0010-7824(02)00536-X","article-title":"A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties","volume":"67","author":"Schramm","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/13625189909040809","article-title":"A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel","volume":"4","author":"Winkler","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.04.013_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000051701","article-title":"Acne resolution rates: results of a single-blind, randomized, controlled, parallel Phase III trial with EE\/CMA (Belara) and EE\/LNG (Microgynon)","volume":"203","author":"Worret","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.contraception.2010.04.013_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0010-7824(98)00008-0","article-title":"Efficacy and safety of the new antiandrogenic oral contraceptive Belara","volume":"57","author":"Zahradnik","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.contraception.2007.12.007","volume":"77","author":"Zahradnik","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib12","first-page":"3","article-title":"The influence of ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg on the thickness and histology of the endometrium","volume":"6","author":"Rabe","year":"2008","journal-title":"JATR"},{"key":"10.1016\/j.contraception.2010.04.013_bib13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.03.014","article-title":"Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study","volume":"76","author":"Schramm","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0002-9378(99)70364-9","article-title":"The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol","volume":"181","author":"Coney","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.04.013_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0010-7824(96)00183-7","article-title":"Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(01)00258-X","article-title":"Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene","volume":"64","author":"Ludicke","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0010-7824(01)00235-9","article-title":"Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel","volume":"64","author":"Endrikat","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0010-7824(96)00137-0","article-title":"Shorter pill-free interval in combined oral contraceptives decreases follicular development","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0010-7824(95)00074-K","article-title":"Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation","volume":"51","author":"Rosenberg","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1067\/mob.2002.122988","article-title":"Acceptance of altering the standard 21-day\/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms","volume":"186","author":"Sulak","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.04.013_bib21","first-page":"94","article-title":"Effects of hormone therapy on the endometrium","volume":"6","author":"Deligdisch","year":"1993","journal-title":"Mod Pathol"},{"key":"10.1016\/j.contraception.2010.04.013_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/13625189609150678","article-title":"The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women","volume":"1","author":"Coenen","year":"1996","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.04.013_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/13625189709167476","article-title":"A study of the influence of a gestodene-containing triphasic oral contraceptive on endometrial morphology","volume":"2","author":"Rabe","year":"1997","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.04.013_bib24","series-title":"Technical Report Series 817: oral contraceptives and neoplasia. Report of the WHO scientific group","first-page":"1","author":"World Health Organization","year":"1992"},{"key":"10.1016\/j.contraception.2010.04.013_bib25","unstructured":"European Medicines Association. Committee for Medicinal Products for Human Use: Guideline on clinical investigation of steroid contraceptives in women. EMEA\/CPMP\/EWP\/519\/98 Rev 1. London 2006:1\u20136."},{"key":"10.1016\/j.contraception.2010.04.013_bib26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.contraception.2010.01.011","article-title":"Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24\/4-day regimen","volume":"81","author":"Brucker","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib27","article-title":"Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate given in a 24\/4-day regimen over 3 cycles","author":"Spona","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.04.013_bib28","first-page":"1915","article-title":"Abnormal uterine bleeding","volume":"69","author":"Albers","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.contraception.2010.04.013_bib29","first-page":"265","article-title":"Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group","volume":"81","author":"Brinton","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.04.013_bib30","first-page":"200","article-title":"Adenocarcinoma of the endometrium in women taking sequential oral contraceptives","volume":"47","author":"Kelley","year":"1976","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.04.013_bib31","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00006254-200405000-00025","article-title":"Endometrial hyperplasia: a review","volume":"59","author":"Montgomery","year":"2004","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.contraception.2010.04.013_bib32","first-page":"503","article-title":"Endometrial carcinoma in young women taking oral contraceptive agents","volume":"46","author":"Silverberg","year":"1975","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.04.013_bib33","first-page":"695","article-title":"The role of hormones in the etiology and prevention of endometrial cancer","volume":"13","author":"Gambrell","year":"1986","journal-title":"Clin Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2010.04.013_bib34","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jnci\/89.15.1110","article-title":"Estrogen\u2013progestin replacement therapy and endometrial cancer","volume":"89","author":"Pike","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.contraception.2010.04.013_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/modpathol.3880050","article-title":"Hormonal pathology of the endometrium","volume":"13","author":"Deligdisch","year":"2000","journal-title":"Mod Pathol"},{"key":"10.1016\/j.contraception.2010.04.013_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tem.2008.02.007","article-title":"Endometrial structural and inflammatory changes with exogenous progestogens","volume":"19","author":"Hickey","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.contraception.2010.04.013_bib37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-2008-1036339","article-title":"Light and electron microscopy changes in the endometrium caused by the administration of a norgestimate-containing oral contraceptive (Cilest)","volume":"46","author":"Rabe","year":"1986","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.contraception.2010.04.013_bib38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13625189709049933","article-title":"The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness","volume":"2","author":"Rabe","year":"1997","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.04.013_bib39","doi-asserted-by":"crossref","first-page":"69402","DOI":"10.1155\/IDOG\/2006\/69402","article-title":"Endometrial histology of depomedroxyprogesterone acetate users: a pilot study","volume":"2006","author":"Thurman","year":"2006","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2010.04.013_bib40","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1477-7827-4-S1-S8","article-title":"Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs)","volume":"4","author":"Chwalisz","year":"2006","journal-title":"Reprod Biol Endocrinol"},{"issue":"Suppl 2","key":"10.1016\/j.contraception.2010.04.013_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/13625189909085264","article-title":"An open-label study of the effects of a 24-day regimen of gestodene 60 microg\/ethinylestradiol 15 microg on endometrial histological findings in healthy women","volume":"4","author":"Oosterbaan","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.04.013_bib42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0015-0282(01)01834-9","article-title":"Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium","volume":"76","author":"Ludicke","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.04.013_bib43","first-page":"3","article-title":"The influence of ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg on the structure and histology of the endometrium","volume":"6","author":"Rabe","year":"2008","journal-title":"J Appl Ther"},{"key":"10.1016\/j.contraception.2010.04.013_bib44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0015-0282(99)00205-8","article-title":"Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity","volume":"72","author":"Sullivan","year":"1999","journal-title":"Fertil Steril"},{"issue":"Supp 1","key":"10.1016\/j.contraception.2010.04.013_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13625180500434962","article-title":"Belara\u2014proven benefits in daily practice","volume":"10","author":"Bitzer","year":"2005","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.04.013_bib46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0010-7824(97)00024-3","article-title":"A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG)","volume":"55","author":"Archer","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.04.013_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003989.pub2","article-title":"20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception","author":"Gallo","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2010.04.013_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0010-7824(94)00010-T","article-title":"Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel","volume":"51","author":"Fotherby","year":"1995","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410001502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410001502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T17:23:20Z","timestamp":1544376200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782410001502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0010782410001502"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2010.04.013","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}